The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
it did work in everybody who had an increase in triglycerides and low HDL cholesterol it worked in that's where the outcome reduction was very interesting which no little if the drug has ever done it reduced several microvascular endpoints in those trials to retinopathy amputations peripheral neuropathy renal disease
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.